Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT

J. Sanz, M. Labopin, J. Versluis, D. Blaise, L. Lazzari, J. Montoro, G. Van Gorkom, P. von dem Borne, L. Sandrine, M. Rovira, P. Reményi, P. Chevallier, M. Kwon, M. Eder, J. Vydra, E. Brissot, A. Spyridonidis, S. Piemontese, M. Mohty, F. Ciceri

. 2025 ; 60 (4) : 529-534. [pub] 20250212

Language English

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25016275

We retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1). These patients received their first hematopoietic stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy). The intermediate-risk cytogenetic group included 1386 (76%) patients, and 608 (34%) had mutated FLT3-ITD. Myeloablative conditioning was used in 930 patients (51%), while 1130 (62%) received an intensified conditioning (score ≥2.5) based on the transplant conditioning intensity (TCI) score. Conditioning intensity using the myeloablative/reduced intensity stratification did not impact transplant outcomes across the entire cohort. However, a higher TCI score was associated with a lower risk of relapse, with no effect on survival. In specific cytogenetic risk groups, a higher TCI score did not influence outcomes in the adverse-risk group. In the intermediate-risk group, the impact varied with FLT3-ITD status. Patients with FLT3-ITD mutation who received a higher TCI showed a beneficial effect on relapse, leukemia-free survival (LFS), and overall survival. Conversely, in FLT3-ITD wild-type patients, more intense conditioning had a detrimental effect on graft-versus-host disease-free, and relapse-free survival with no effect on other outcomes. In conclusion, for AML patients in CR1 undergoing HSCT with PTCy, it is crucial to consider cytogenetic risk and molecular status when selecting the conditioning regimen. Intensive conditioning should be considered for patients with intermediate-risk cytogenetics and mutated FLT3-ITD but should probably be avoided for those with wild-type FLT3-ITD.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016275
003      
CZ-PrNML
005      
20250731092758.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-025-02527-z $2 doi
035    __
$a (PubMed)39939431
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a x
100    1_
$a Sanz, Jaime $u Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina, Universitat de Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain. Jaime.Sanz@uv.es $1 https://orcid.org/0000000169344619
245    10
$a Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT / $c J. Sanz, M. Labopin, J. Versluis, D. Blaise, L. Lazzari, J. Montoro, G. Van Gorkom, P. von dem Borne, L. Sandrine, M. Rovira, P. Reményi, P. Chevallier, M. Kwon, M. Eder, J. Vydra, E. Brissot, A. Spyridonidis, S. Piemontese, M. Mohty, F. Ciceri
520    9_
$a We retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1). These patients received their first hematopoietic stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy). The intermediate-risk cytogenetic group included 1386 (76%) patients, and 608 (34%) had mutated FLT3-ITD. Myeloablative conditioning was used in 930 patients (51%), while 1130 (62%) received an intensified conditioning (score ≥2.5) based on the transplant conditioning intensity (TCI) score. Conditioning intensity using the myeloablative/reduced intensity stratification did not impact transplant outcomes across the entire cohort. However, a higher TCI score was associated with a lower risk of relapse, with no effect on survival. In specific cytogenetic risk groups, a higher TCI score did not influence outcomes in the adverse-risk group. In the intermediate-risk group, the impact varied with FLT3-ITD status. Patients with FLT3-ITD mutation who received a higher TCI showed a beneficial effect on relapse, leukemia-free survival (LFS), and overall survival. Conversely, in FLT3-ITD wild-type patients, more intense conditioning had a detrimental effect on graft-versus-host disease-free, and relapse-free survival with no effect on other outcomes. In conclusion, for AML patients in CR1 undergoing HSCT with PTCy, it is crucial to consider cytogenetic risk and molecular status when selecting the conditioning regimen. Intensive conditioning should be considered for patients with intermediate-risk cytogenetics and mutated FLT3-ITD but should probably be avoided for those with wild-type FLT3-ITD.
650    _2
$a lidé $7 D006801
650    12
$a cyklofosfamid $x terapeutické užití $x aplikace a dávkování $x farmakologie $7 D003520
650    12
$a akutní myeloidní leukemie $x terapie $x genetika $x mortalita $7 D015470
650    12
$a příprava pacienta k transplantaci $x metody $7 D019172
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    12
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a senioři $7 D000368
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u EBMT Paris Office, Hospital Saint Antoine, Paris, France $1 https://orcid.org/0000000345144748
700    1_
$a Versluis, Jurjen $u Erasmus MC Cancer Institute, Rotterdam, The Netherlands $1 https://orcid.org/0000000323721663
700    1_
$a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire-Marseille, Marseille, France $1 https://orcid.org/0000000256849447
700    1_
$a Lazzari, Lorenzo $u Hematology and Bone Marrow transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy $1 https://orcid.org/0000000308440708
700    1_
$a Montoro, Juan $u Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina, Universitat de Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain $1 https://orcid.org/0000000300248068
700    1_
$a Van Gorkom, Gwendolyn $u University Hospital Maastricht, Maastricht, The Netherlands
700    1_
$a von dem Borne, Peter $u Leiden University Medical Center, Leiden, The Netherlands $1 https://orcid.org/0000000274707346
700    1_
$a Sandrine, Loron $u Centre Hospitalier Lyon Sud, Lyon, France
700    1_
$a Rovira, Montserrat $u BMT Unit, Department of Haematology, Institute of Haematology and Oncology, IDIBAPS, Hospital Clinic, University of Barcelona, Josep Carreras Leukaemia Research Foundation, Barcelona, Spain
700    1_
$a Reményi, Péter $u Dél-pesti Centrumkórház, Budapest, Hungary
700    1_
$a Chevallier, Patrice $u CHU Nantes, Nantes, France $1 https://orcid.org/0000000331425581
700    1_
$a Kwon, Mi $u Hospital Gregorio Marañón, Madrid, Spain $1 https://orcid.org/0000000238557774
700    1_
$a Eder, Matthias $u Hannover Medical School, Hannover, Germany
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
700    1_
$a Brissot, Eolia $u Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris, France $1 https://orcid.org/000000034471418X
700    1_
$a Spyridonidis, Alexandros $u Hematology, BMT and Institute of Cellular Therapy, University of Patras, Patras, Greece $1 https://orcid.org/0000000330972532
700    1_
$a Piemontese, Simona $u Hematology and Bone Marrow transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy $1 https://orcid.org/0000000259080792
700    1_
$a Mohty, Mohamad $u Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris, France $1 https://orcid.org/000000027264808X $7 xx0317729
700    1_
$a Ciceri, Fabio $u Hematology and Bone Marrow transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy $u Vita-Salute San Raffaele University, Milano, Italy
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 60, č. 4 (2025), s. 529-534
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39939431 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731092753 $b ABA008
999    __
$a ok $b bmc $g 2366848 $s 1253400
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 60 $c 4 $d 529-534 $e 20250212 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options